Description
💉 Bocouture 100U – Precision Botulinum Toxin Type A for Natural-Looking Wrinkle Correction
Bocouture 100U is a purified botulinum toxin type A injectable, developed specifically for aesthetic and therapeutic applications. Manufactured by Merz Pharmaceuticals, Bocouture is known for its high purity, free from complexing proteins, making it an ideal choice for patients seeking a lower risk of immune resistance.
Clinicians and dermatologists use Bocouture to treat glabellar lines (frown lines), forehead wrinkles, and crow’s feet, providing patients with smoother, younger-looking skin. Bocouture delivers natural facial expression without the “frozen” look, making it a preferred choice in modern aesthetic treatments.
🌟 Benefits of Bocouture 100U
-
✅ Highly purified formula with no complexing proteins
-
✅ Reduces moderate to severe dynamic facial lines
-
✅ Smooth, natural-looking results with full facial mobility
-
✅ Quick onset – results often visible within 2–4 days
-
✅ Long-lasting effects that typically last 3–4 months
-
✅ Lower immunogenicity compared to other botulinum toxins
💡 How Bocouture Works
Bocouture works by temporarily blocking nerve signals to targeted facial muscles, preventing them from contracting. This relaxation of muscles allows the overlying skin to smooth out, reducing the appearance of lines and wrinkles. Administered by trained professionals, the treatment is quick and virtually painless.
A single vial of Bocouture 100 Units can be used across multiple facial areas, depending on dosage and treatment goals. Its formulation ensures consistent, safe, and reliable outcomes.
⚠️ Important Safety Information
-
Administer only by qualified professionals in a clinical setting
-
Temporary side effects may include minor swelling, redness, or localized discomfort
-
Not suitable for use during pregnancy or breastfeeding
-
Inform your provider of any neuromuscular conditions or medications before treatment
-
Keep vials refrigerated and use immediately after reconstitution
Reviews
There are no reviews yet.